Seeking Alpha

Pacira Pharma releases more data on the benefits of Exparel

  • Pacira Pharmaceuticals (PCRX) is out with results from Phase 4 studies of Exparel in laparoscopic colectomy patients.
  • The company says the data "reinforce findings from [the] IMPROVE trials ... demonstrating the opioid-sparing and economic benefits of Exparel."
  • Patients receiving the Exparel-based multimodal regimen experienced:"A 64 mg reduction in mean opioid consumption," "a 1-day reduction in median length of hospital stay," "significantly fewer opioid-related adverse events," and "a $1,784 reduction in mean hospitalization costs." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector